{
    "initial_questions": "Here are two multiple-choice questions for each Bloom's Taxonomy level based on the content analysis provided:\n\n**Knowledge (Recall)**\n\n1) In what year did Frances Oldham Kelsey join the FDA?\n    - A: 1950\n    - B: 1955\n    - C: 1960\n    - D: 1965\n[Correct answer]: C\n\n2) What was thalidomide initially developed for in Germany?\n    - A: Treating cancer\n    - B: Relieving pain\n    - C: As a sedative\n    - D: Lowering blood pressure\n[Correct answer]: C\n\n**Comprehension (Understanding)**\n\n1) What was the common belief among experts in 1960 regarding the placental barrier?\n    - A: It allowed all substances to pass from mother to fetus.\n    - B: It shielded the fetus from all harm.\n    - C: It only allowed certain substances to pass through.\n    - D: It was not a significant factor in fetal development.\n[Correct answer]: B\n\n2) What was the outcome of Merrell's attempts to convince Kelsey to approve thalidomide?\n    - A: Kelsey eventually approved the application.\n    - B: Merrell successfully appealed the rejection.\n    - C: The company withdrew their application.\n    - D: The FDA overruled Kelsey's decision.\n[Correct answer]: C\n\n**Application (Real-world scenarios)**\n\n1) A new pharmaceutical company is developing a drug that has shown promise in treating a specific disease. However, the company has not conducted rigorous testing to ensure the drug's safety. What should the FDA do in this scenario?\n    - A: Approve the drug immediately to help patients.\n    - B: Reject the application due to inadequate data.\n    - C: Allow the company to conduct further testing while the drug is on the market.\n    - D: Reduce the required testing period to speed up the approval process.\n[Correct answer]: B\n\n2) A regulatory agency is considering changes to its approval process for new drugs. What should be the primary consideration in making these changes?\n    - A: Reducing the time it takes to approve new drugs.\n    - B: Increasing the profits of pharmaceutical companies.\n    - C: Ensuring the safety of patients and the general public.\n    - D: Simplifying the application process for companies.\n[Correct answer]: C\n\n**Analysis (Relationships, contrasts, cause-and-effect)**\n\n1) What was the relationship between Kelsey's research on fetal safety and her decision to reject Merrell's application?\n    - A: Her research had no impact on her decision.\n    - B: Her research showed that thalidomide was safe for fetuses.\n    - C: Her research demonstrated that drugs could pass from mother to fetus, influencing her decision.\n    - D: Her research was focused on a different aspect of pharmacology.\n[Correct answer]: C\n\n2) What was the cause-and-effect connection between thalidomide's use and the resulting birth defects?\n    - A: Thalidomide had no causal link to birth defects.\n    - B: Thalidomide caused minor birth defects, but they were rare.\n    - C: Thalidomide caused severe birth defects, including nerve damage and limb abnormalities.\n    - D: The connection between thalidomide and birth defects is still unknown.\n[Correct answer]: C\n\n**Synthesis (Combining ideas)**\n\n1) What combination of factors contributed to Kelsey's significant impact on public health?\n    - A: Her educational background and research experience.\n    - B: Her FDA role and industry connections.\n    - C: Her educational background, research experience, and FDA role.\n    - D: Her personal interests and motivations.\n[Correct answer]: C\n\n2) What intersection of factors shaped the response to the thalidomide tragedy?\n    - A: Science, policy, and public awareness.\n    - B: Economics, politics, and social norms.\n    - C: Technology, media, and public opinion.\n    - D: Industry interests, regulatory agencies, and patient advocacy.\n[Correct answer]: A\n\n**Evaluation (Judgment, critique, justification)**\n\n1) How would you evaluate the ethics of Merrell's actions in attempting to convince Kelsey to approve thalidomide despite inadequate data?\n    - A: Merrell's actions were justified, as they were trying to help patients.\n    - B: Merrell's actions were neutral, as they were simply following industry practices.\n    - C: Merrell's actions were unethical, as they prioritized profits over patient safety.\n    - D: Merrell's actions were irrelevant, as the FDA ultimately made the decision.\n[Correct answer]: C\n\n2) How would you justify the FDA's decision to reject Merrell's application and the subsequent changes to regulations?\n    - A: The FDA overreacted, and the changes were unnecessary.\n    - B: The FDA made a reasonable decision, but the changes were too restrictive.\n    - C: The FDA made a necessary decision, and the changes improved public safety.\n    - D: The FDA had no basis for rejecting the application, and the changes were arbitrary.\n[Correct answer]: C"
}